What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
John V. Heymach focuses on Cancer research, Lung cancer, Cancer, Internal medicine and Oncology.
His biological study spans a wide range of topics, including Molecular biology, KRAS, Immunology and Epidermal growth factor receptor.
His study in Lung cancer is interdisciplinary in nature, drawing from both Epithelial–mesenchymal transition, Targeted therapy, Randomized controlled trial and Adenocarcinoma.
His work carried out in the field of Cancer brings together such families of science as Blockade, CD8 and Pathology.
His Internal medicine research incorporates themes from Surgery and Drug resistance.
John V. Heymach interconnects Clinical trial, Phases of clinical research, Vandetanib, Carcinoma and Docetaxel in the investigation of issues within Oncology.
His most cited work include:
- Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (2762 citations)
- Comprehensive genomic characterization of squamous cell lung cancers (2590 citations)
- Molecular origins of cancer: Lung cancer (1498 citations)
What are the main themes of his work throughout his whole career to date?
Cancer research, Internal medicine, Lung cancer, Oncology and Cancer are his primary areas of study.
His Cancer research study integrates concerns from other disciplines, such as Immunology, Immune system, Pathology, KRAS and Adenocarcinoma.
His Chemotherapy, Radiation therapy, Phases of clinical research and Vandetanib study in the realm of Internal medicine interacts with subjects such as In patient.
The study incorporates disciplines such as Targeted therapy, Carcinoma and Immunotherapy in addition to Lung cancer.
His Oncology research incorporates elements of Biomarker, Clinical trial, Lung and Cytokine.
The concepts of his Cancer study are interwoven with issues in PI3K/AKT/mTOR pathway and Angiogenesis.
He most often published in these fields:
- Cancer research (46.76%)
- Internal medicine (38.99%)
- Lung cancer (38.99%)
What were the highlights of his more recent work (between 2019-2021)?
- Lung cancer (38.99%)
- Internal medicine (38.99%)
- Cancer research (46.76%)
In recent papers he was focusing on the following fields of study:
John V. Heymach spends much of his time researching Lung cancer, Internal medicine, Cancer research, Oncology and Cancer.
His work in the fields of Lung cancer, such as Non small cell, overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2.
His Internal medicine study frequently links to related topics such as Gastroenterology.
His Cancer research study also includes fields such as
- Cytotoxic T cell and Carcinoma most often made with reference to Immune system,
- Adenocarcinoma and related DNA methylation.
His Oncology research is multidisciplinary, relying on both Pembrolizumab, Nivolumab, Radiation therapy and Disease.
John V. Heymach studies KRAS which is a part of Cancer.
Between 2019 and 2021, his most popular works were:
- Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. (50 citations)
- Comprehensive T cell repertoire characterization of non-small cell lung cancer (41 citations)
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. (28 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer research and Immunotherapy.
His studies deal with areas such as Immunohistochemistry, Exome sequencing, Carcinoma, Metastasis and Lung as well as Lung cancer.
His biological study deals with issues like Gastroenterology, which deal with fields such as Prospective cohort study and Progression-free survival.
His studies in Oncology integrate themes in fields like Pembrolizumab, Biopsy, Clinical trial and PD-L1.
The Cancer research study combines topics in areas such as Cell, DNA methylation, Immune system, Atypical adenomatous hyperplasia and Targeted therapy.
His Methylation study combines topics in areas such as Carcinogenesis and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
